公开(公告)号：US20200297863A1

公开(公告)日：2020-09-24

申请号：US16643528

申请日：2018-09-04

Applicant: AbbVie Inc.

Inventor： Edward Reilly ,  Mark Anderson

IPC: A61K47/68 ,  C07K16/28

Abstract: Provided herein are antibody-drug conjugates that bind EGFR, in particular human EGFR, their methods of making, and their uses to treat patients having cancer.

公开(公告)号：US10184003B2

公开(公告)日：2019-01-22

申请号：US15176137

申请日：2016-06-07

Applicant: AbbVie Inc.

Inventor： Mark Anderson ,  Jieyi Wang ,  Archana Thakur ,  Debra Chao ,  Chung-Ming Hsieh ,  Qian Zhang ,  Edward B. Reilly ,  Enrico L. Digiammarino ,  Kenton L. Longenecker ,  Russell A. Judge ,  David A. Egan ,  Charles W. Hutchins

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

公开(公告)号：US10112999B2

公开(公告)日：2018-10-30

申请号：US15946774

申请日：2018-04-06

Applicant: AbbVie Inc.

Inventor： Edward B. Reilly ,  Mark Anderson

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.

公开(公告)号：US09725515B2

公开(公告)日：2017-08-08

申请号：US14138906

申请日：2013-12-23

Applicant: AbbVie Inc.

Inventor： Mark Anderson ,  Jieyi Wang ,  Archana Thakur ,  Debra Chao ,  Chung-Ming Hsieh ,  Qian Zhang ,  Edward B. Reilly

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2869 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

公开(公告)号：US20180244789A1

公开(公告)日：2018-08-30

申请号：US15946774

申请日：2018-04-06

Applicant: AbbVie Inc.

Inventor： Edward B. Reilly ,  Mark Anderson

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52

Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.